| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
1 Division of Epigenetics, Deutsches Krebsforschungszentrum, Heidelberg, Germany and 2 Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany
Requests for reprints: Frank Lyko, Deutsches Krebsforschungszentrum Im Neuenheimer Feld 580, 69120 Heidelberg, Germany. Phone: 49-6221-42-3800; Fax: 49-6221-42-3802; E-mail: f.lyko{at}dkfz.de.
DNA methyltransferase inhibitors represent promising new drugs for cancer therapies. The first of these compounds (5-azacytidine, Vidaza) has recently been approved as an antitumor agent, and others are presently in various stages of their preclinical or clinical development. Most of the archetypal inhibitors have been established and characterized in different experimental systems, which has thus far precluded their direct comparison. We have now established defined experimental conditions that allowed a comparative analysis of the six most widely known DNA methyltransferase inhibitors: 5-azacytidine (5-aza-CR), 5-aza-2'-deoxycytidine (5-aza-CdR), zebularine, procaine, (–)-epigallocatechin-3-gallate (EGCG), and RG108. Of these, 5-aza-CR, 5-aza-CdR, zebularine, and EGCG were found to exhibit significant cytotoxicity in human cancer cell lines. 5-aza-CdR and EGCG were also found to be genotoxic, as evidenced by the induction of micronuclei. In addition, 5-aza-CR, 5-aza-CdR, zebularine, and RG108 caused concentration-dependent demethylation of genomic DNA, whereas procaine and EGCG failed to induce significant effects. Finally, the experiments in cancer cell lines were complemented by a cell-free in vitro assay with purified recombinant DNA methyltransferase, which indicated that RG108 is the only drug capable of direct enzyme inhibition. These results show a substantial diversity in the molecular activities of DNA methyltransferase inhibitors and provide valuable insights into the developmental potential of individual drugs. (Cancer Res 2006; 66(5): 2794-800)
This article has been cited by other articles:
|
|
 |
|
  M. Schaefer, S. Hagemann, K. Hanna, and F. Lyko Azacytidine Inhibits RNA Methylation at DNMT2 Target Sites in Human Cancer Cell Lines Cancer Res., October 15, 2009; 69(20): 8127 - 8132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Evison, R. A. Bilardi, F. C. K. Chiu, G. Pezzoni, D. R. Phillips, and S. M. Cutts CpG methylation potentiates pixantrone and doxorubicin-induced DNA damage and is a marker of drug sensitivity Nucleic Acids Res., October 1, 2009; 37(19): 6355 - 6370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. J. Issa and H. M. Kantarjian Targeting DNA Methylation Clin. Cancer Res., June 15, 2009; 15(12): 3938 - 3946. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. GAO, Z. XU, M.-S. HUNG, Y.-C. LIN, T. WANG, M. GONG, X. ZHI, D. M. JABLON, and L. YOU Promoter Demethylation of WIF-1 by Epigallocatechin-3-gallate in Lung Cancer Cells Anticancer Res, June 1, 2009; 29(6): 2025 - 2030. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Datta, K. Ghoshal, W. A. Denny, S. A. Gamage, D. G. Brooke, P. Phiasivongsa, S. Redkar, and S. T. Jacob A New Class of Quinoline-Based DNA Hypomethylating Agents Reactivates Tumor Suppressor Genes by Blocking DNA Methyltransferase 1 Activity and Inducing Its Degradation Cancer Res., May 15, 2009; 69(10): 4277 - 4285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rius, C. Stresemann, D. Keller, M. Brom, E. Schirrmacher, D. Keppler, and F. Lyko Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation Mol. Cancer Ther., January 1, 2009; 8(1): 225 - 231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Stresemann, I. Bokelmann, U. Mahlknecht, and F. Lyko Azacytidine causes complex DNA methylation responses in myeloid leukemia Mol. Cancer Ther., September 1, 2008; 7(9): 2998 - 3005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Issa Cancer Prevention: Epigenetics Steps Up to the Plate Cancer Prevention Research, September 1, 2008; 1(4): 219 - 222. [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Palii, B. O. Van Emburgh, U. T. Sankpal, K. D. Brown, and K. D. Robertson DNA Methylation Inhibitor 5-Aza-2'-Deoxycytidine Induces Reversible Genome-Wide DNA Damage That Is Distinctly Influenced by DNA Methyltransferases 1 and 3B Mol. Cell. Biol., January 15, 2008; 28(2): 752 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. P. Moiseeva, G. M. Almeida, G. D.D. Jones, and M. M. Manson Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells Mol. Cancer Ther., November 1, 2007; 6(11): 3071 - 3079. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Zorn, K. J. Wojno, M. T. McCabe, R. Kuefer, J. E. Gschwend, and M. L. Day 5-Aza-2'-Deoxycytidine Delays Androgen-Independent Disease and Improves Survival in the Transgenic Adenocarcinoma of the Mouse Prostate Mouse Model of Prostate Cancer Clin. Cancer Res., April 1, 2007; 13(7): 2136 - 2143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fang, D. Chen, and C. S. Yang Dietary Polyphenols May Affect DNA Methylation J. Nutr., January 1, 2007; 137(1): 223S - 228S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-J. Heidebrecht, A. Claviez, M. L. Kruse, M. Pollmann, F. Buck, S. Harder, M. Tiemann, W. Dorffel, and R. Parwaresch Characterization and Expression of CT45 in Hodgkin's Lymphoma. Clin. Cancer Res., August 15, 2006; 12(16): 4804 - 4811. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
